P. Arvis

发表

Moxifloxacin in Complicated Skin and Skin Structure Infections (cSSSIs): A Prospective, International, Non-Interventional, Observational Study

J. Bogner, Ammar Kutaiman, Melanie Esguerra-Alcalen, 2013, Advances in Therapy.

Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study

D. Nathwani, I. Gyssens, N. Schaper, 2012, Infection.

Update on the Cardiac Safety of Moxifloxacin

W. Haverkamp, P. Arvis, Frank Kruesmann, 2012, Current drug safety.

A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology

A. Anzueto, M. Miravitlles, P. Arvis, 2011, International journal of chronic obstructive pulmonary disease.

Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia

S. Urien, B. Bruguerolle, B. Lacarelle, 2003, Clinical pharmacology and therapeutics.

Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections

J. Bogner, P. Arvis, C. Amábile-Cuevas, 2009, Infection.

Clinical Efficacy of Moxifloxacin Versus Comparator Therapies for Community-Acquired Pneumonia Caused by Legionella spp.

P. Arvis, J. Garau, A. Fritsch, 2010, Journal of chemotherapy.

Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis

M. Miravitlles, P. Arvis, S. Choudhri, 2011, European Respiratory Journal.

Characterisation of Patients Receiving Moxifloxacin for Acute Bacterial Rhinosinusitis in Clinical Practice: Results from an International, Observational Cohort Study

R. Mösges, M. Desrosiers, S. Heldner, 2013, PloS one.

Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.

P. Arvis, P. Petitpretz, J. Moita, 2001, Chest.

An Analysis of 14 Years of Clinical Data

P. Tulkens, P. Arvis, Frank Kruesmann, 2012 .

Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial

P. Arvis, J. Ross, T. Paszkowski, 2006, Sexually Transmitted Infections.

Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study.

J. Tellado, J. D. De Waele, P. Arvis, 2013, International journal of antimicrobial agents.

Efficacy and safety of moxifloxacin in hospitalized patients with secondary peritonitis: pooled analysis of four randomized phase III trials.

J. Tellado, J. Solomkin, J. D. De Waele, 2014, Surgical infections.

Comparison of the efficacy and safety of faropenem daloxate and cefuroxime axetil for the treatment of acute bacterial maxillary sinusitis in adults

P. Arvis, P. Géhanno, P. Nikolaidis, 2003, European Archives of Oto-Rhino-Laryngology.

A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections

D. Nathwani, I. Gyssens, N. Schaper, 2011, The Journal of antimicrobial chemotherapy.

Moxifloxacin Safety

Paul M. Tulkens, P. Tulkens, P. Arvis, 2012, Drugs in R&D.

Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study

P. Arvis, P. Judlin, P. Reimnitz, 2010, BJOG : an international journal of obstetrics and gynaecology.

A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus.

J. Pagès, H. Stass, P. Arvis, 2002, The Journal of antimicrobial chemotherapy.

Moxifloxacin Efficacy and Vitreous Penetration in a Rabbit Model of Staphylococcus aureus Endophthalmitis and Effect on Gene Expression of Leucotoxins and Virulence Regulator Factors

M. Ploy, P. Arvis, J. Peter, 2003, Antimicrobial Agents and Chemotherapy.

Diffusion of Oral and Intravenous 400 mg Once-Daily Moxifloxacin into Lung Tissue at Pharmacokinetic Steady-State

J. Velly, J. Jougon, D. Breilh, 2003, Journal of chemotherapy.

A role for TLR1, TLR2 and NOD2 in cytokine induction by Bacteroides fragilis.

M. Oosting, L. Joosten, M. Netea, 2012, Cytokine.

Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results

A. Anzueto, M. Miravitlles, P. Arvis, 2011, European Respiratory Journal.

Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis

P. Sagnier, T. Schaberg, R. Wilson, 2006, Thorax.

Prognostic factors for clinical failure of exacerbations in elderly outpatients with moderate-to-severe COPD

A. Anzueto, M. Miravitlles, P. Arvis, 2015, International journal of chronic obstructive pulmonary disease.

Digital tool to identify and monitor regorafenib-associated hand-foot skin reactions: A proof-of-concept study protocol.

V. Bourgeois, M. Palma, R. Coriat, 2023, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.

J. Carlet, A. Torres, H. Lode, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults

J. Klossek, P. Arvis, M. Leberre, 2003, The Journal of Laryngology & Otology.

Efficacy of moxifloxacin in the treatment of diabetic foot infections: results of the RELIEF study

D. Nathwani, I. Gyssens, N. Schaper, 2010 .

Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease

A. Anzueto, M. Miravitlles, S. Sethi, 2015, Infection.

Efficacy and safety of moxifloxacin in patients with secondary peritonitis: pooled analysis of four randomized Phase III clinical trials.

J. Tellado, J. Solomkin, P. Arvis, 2012 .